Cargando…
SARS-CoV-2 Seroprevalence in Germany: results from the second wave of the RKI-SOEP study: Elisabetta Mercuri
INTRODUCTION: The first wave of the “Corona Monitoring bundesweit” (RKI-SOEP) study showed that shortly before the start of the German vaccination program only about 2% of adults (> 18 years) had already experienced SARS-CoV-2 infection and more than half of these cases had been detected and noti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593651/ http://dx.doi.org/10.1093/eurpub/ckac129.047 |
_version_ | 1784815214899757056 |
---|---|
author | Mercuri, E Poethko-Müller, C Schaffrath Rosario, A Schmid, L Schlaud, M Gößwald, A |
author_facet | Mercuri, E Poethko-Müller, C Schaffrath Rosario, A Schmid, L Schlaud, M Gößwald, A |
author_sort | Mercuri, E |
collection | PubMed |
description | INTRODUCTION: The first wave of the “Corona Monitoring bundesweit” (RKI-SOEP) study showed that shortly before the start of the German vaccination program only about 2% of adults (> 18 years) had already experienced SARS-CoV-2 infection and more than half of these cases had been detected and notified. The objectives of the second wave of this study are to further investigate the spread of SARS-CoV-2 in Germanýs population aged over 14 years. It aims to determine the seroprevalence of infection- and vaccine-induced IgG antibodies against SARS-CoV-2. Finally, it examines health, demographic and socioeconomic risk and protective factors for infection and vaccine acceptance. METHODS: From November 2021 to February 2022, the second wave of this cross-sectional study collected biospecimens (capillary blood samples) and interview data, including information on infection and vaccination, from a nationwide population sample drawn from the German Socio-Economic Panel (SOEP). The dried self-collected blood samples were then analyzed for the detection of SARS-CoV-2 IgG antibodies by Euroimmun ELISA assay. RESULTS: Based on preliminary, unweighted data of around 11,000 participants aged >14 years (52% response rate), we expect the final seroprevalence of SARS-CoV-2 antibodies to be in the range of 80 to 90%. Thus, around 10 to 20% of the German population may still be susceptible to a severe disease progression because they are neither infected nor vaccinated. Final results, weighted for non-response and adjusted for test sensitivity and specificity, will be presented. CONCLUSIONS: The RKI-SOEP-2 study will be pivotal in both, contributing to an improved understanding of SARS-CoV-2 propagation in different regional and sub-group settings and in identifying vulnerable target groups that need to be protected against future infections. KEY MESSAGES: • Dried blood self-sampling in a nationwide sample is a robust tool to estimate seroprevalence at a population level. • As of February 2022, presumably 80 to 90% of the German population has previously been infected and/or vaccinated against SARS-CoV-2. |
format | Online Article Text |
id | pubmed-9593651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95936512022-11-04 SARS-CoV-2 Seroprevalence in Germany: results from the second wave of the RKI-SOEP study: Elisabetta Mercuri Mercuri, E Poethko-Müller, C Schaffrath Rosario, A Schmid, L Schlaud, M Gößwald, A Eur J Public Health Parallel Programme INTRODUCTION: The first wave of the “Corona Monitoring bundesweit” (RKI-SOEP) study showed that shortly before the start of the German vaccination program only about 2% of adults (> 18 years) had already experienced SARS-CoV-2 infection and more than half of these cases had been detected and notified. The objectives of the second wave of this study are to further investigate the spread of SARS-CoV-2 in Germanýs population aged over 14 years. It aims to determine the seroprevalence of infection- and vaccine-induced IgG antibodies against SARS-CoV-2. Finally, it examines health, demographic and socioeconomic risk and protective factors for infection and vaccine acceptance. METHODS: From November 2021 to February 2022, the second wave of this cross-sectional study collected biospecimens (capillary blood samples) and interview data, including information on infection and vaccination, from a nationwide population sample drawn from the German Socio-Economic Panel (SOEP). The dried self-collected blood samples were then analyzed for the detection of SARS-CoV-2 IgG antibodies by Euroimmun ELISA assay. RESULTS: Based on preliminary, unweighted data of around 11,000 participants aged >14 years (52% response rate), we expect the final seroprevalence of SARS-CoV-2 antibodies to be in the range of 80 to 90%. Thus, around 10 to 20% of the German population may still be susceptible to a severe disease progression because they are neither infected nor vaccinated. Final results, weighted for non-response and adjusted for test sensitivity and specificity, will be presented. CONCLUSIONS: The RKI-SOEP-2 study will be pivotal in both, contributing to an improved understanding of SARS-CoV-2 propagation in different regional and sub-group settings and in identifying vulnerable target groups that need to be protected against future infections. KEY MESSAGES: • Dried blood self-sampling in a nationwide sample is a robust tool to estimate seroprevalence at a population level. • As of February 2022, presumably 80 to 90% of the German population has previously been infected and/or vaccinated against SARS-CoV-2. Oxford University Press 2022-10-25 /pmc/articles/PMC9593651/ http://dx.doi.org/10.1093/eurpub/ckac129.047 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Parallel Programme Mercuri, E Poethko-Müller, C Schaffrath Rosario, A Schmid, L Schlaud, M Gößwald, A SARS-CoV-2 Seroprevalence in Germany: results from the second wave of the RKI-SOEP study: Elisabetta Mercuri |
title | SARS-CoV-2 Seroprevalence in Germany: results from the second wave of the RKI-SOEP study: Elisabetta Mercuri |
title_full | SARS-CoV-2 Seroprevalence in Germany: results from the second wave of the RKI-SOEP study: Elisabetta Mercuri |
title_fullStr | SARS-CoV-2 Seroprevalence in Germany: results from the second wave of the RKI-SOEP study: Elisabetta Mercuri |
title_full_unstemmed | SARS-CoV-2 Seroprevalence in Germany: results from the second wave of the RKI-SOEP study: Elisabetta Mercuri |
title_short | SARS-CoV-2 Seroprevalence in Germany: results from the second wave of the RKI-SOEP study: Elisabetta Mercuri |
title_sort | sars-cov-2 seroprevalence in germany: results from the second wave of the rki-soep study: elisabetta mercuri |
topic | Parallel Programme |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593651/ http://dx.doi.org/10.1093/eurpub/ckac129.047 |
work_keys_str_mv | AT mercurie sarscov2seroprevalenceingermanyresultsfromthesecondwaveoftherkisoepstudyelisabettamercuri AT poethkomullerc sarscov2seroprevalenceingermanyresultsfromthesecondwaveoftherkisoepstudyelisabettamercuri AT schaffrathrosarioa sarscov2seroprevalenceingermanyresultsfromthesecondwaveoftherkisoepstudyelisabettamercuri AT schmidl sarscov2seroprevalenceingermanyresultsfromthesecondwaveoftherkisoepstudyelisabettamercuri AT schlaudm sarscov2seroprevalenceingermanyresultsfromthesecondwaveoftherkisoepstudyelisabettamercuri AT goßwalda sarscov2seroprevalenceingermanyresultsfromthesecondwaveoftherkisoepstudyelisabettamercuri AT sarscov2seroprevalenceingermanyresultsfromthesecondwaveoftherkisoepstudyelisabettamercuri |